Reddy et al. [57] observed in their retrospective analysis that groups of 35 patients treated with mFOLFIRINOX chemotherapy, gemcitabine and nab-paclitaxel or gemcitabine and capecitabine followed by SBRT with KRAS G12V and CDKN2A showed a better rate of pathological tumor regression in NAT than patients treated with others. The gene discussed is KRAS; the disease is neoplasm.